SG11201901472TA - Combination therapies for the treatment of hepatocellular carcinoma - Google Patents

Combination therapies for the treatment of hepatocellular carcinoma

Info

Publication number
SG11201901472TA
SG11201901472TA SG11201901472TA SG11201901472TA SG11201901472TA SG 11201901472T A SG11201901472T A SG 11201901472TA SG 11201901472T A SG11201901472T A SG 11201901472TA SG 11201901472T A SG11201901472T A SG 11201901472TA SG 11201901472T A SG11201901472T A SG 11201901472TA
Authority
SG
Singapore
Prior art keywords
international
pct
hepatocellular carcinoma
treatment
massachusetts
Prior art date
Application number
SG11201901472TA
Inventor
Anand Selvaraj
Peter Smith
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of SG11201901472TA publication Critical patent/SG11201901472TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

PUBLISHEDUNDER THE PATENT COOPERATION TREATY (PCT) °mons °nolo olll nail molommom oimIE () International Publication Number WO 2018/039324 Al WIPO I PCT (51) International Patent Classification: A61K 45/06 (2006.01) A61K 31/519 (2006.01) A61K 31/506 (2006.01) A61K 31/405 (2006.01) A61K 31/445 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/US2017/048183 (22) International Filing Date: 23 August 2017 (23.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/378,455 23 August 2016 (23.08.2016) US (71) Applicant: EISAI R&D MANAGEMENT CO., LTD. [JP/JP]; 6-10 Koishikawa, 4-Chome, Bunkyo-ku, Tokyo, 112-8088 (JP). (72) Inventors; and (71) Applicants (for US only): SELVARAJ, Anand [US/US]; 4 Crawford Street, Apt. 10, Cambridge, Massachusetts 02139 (US). SMITH, Peter [US/US]; 173A Franklin Street, Ar- lington, Massachusetts 02474 (US). (74) Agent: STEWART, Duane A.; Buchanan Ingersoll & Rooney PC, P.O. Box 1404, Alexandria, Virginia 22313-1404 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) O 1-1 O (54) Title: COMBINATION THERAPIES FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA \" (57) : Provided herein is a combination therapy useful for the treatment hepatocellular carcinoma and/or intrahepatic cholan- C giocarcinoma. The combination comprises an FGFR4 inhibitor and a CDK 4/6 inhibitor. (12) INTERNATIONAL APPLICATION (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 March 2018 (01.03.2018)
SG11201901472TA 2016-08-23 2017-08-23 Combination therapies for the treatment of hepatocellular carcinoma SG11201901472TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662378455P 2016-08-23 2016-08-23
PCT/US2017/048183 WO2018039324A1 (en) 2016-08-23 2017-08-23 Combination therapies for the treatment of hepatocellular carcinoma

Publications (1)

Publication Number Publication Date
SG11201901472TA true SG11201901472TA (en) 2019-03-28

Family

ID=59772765

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201901472TA SG11201901472TA (en) 2016-08-23 2017-08-23 Combination therapies for the treatment of hepatocellular carcinoma

Country Status (14)

Country Link
US (1) US20190175598A1 (en)
EP (1) EP3503923B1 (en)
JP (1) JP7190425B2 (en)
KR (1) KR102466192B1 (en)
CN (1) CN109803684B (en)
AU (1) AU2017315357B2 (en)
BR (1) BR112019003722A2 (en)
CA (1) CA3034875C (en)
ES (1) ES2966469T3 (en)
IL (1) IL264950B2 (en)
MX (1) MX2019002115A (en)
RU (1) RU2769251C2 (en)
SG (1) SG11201901472TA (en)
WO (1) WO2018039324A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019205821B2 (en) 2018-01-08 2024-07-18 G1 Therapeutics, Inc. G1T38 superior dosage regimes
AU2019269159A1 (en) 2018-05-14 2020-11-19 Pfizer Inc. Oral solution formulation
TW202128173A (en) * 2019-10-09 2021-08-01 美商G1治療公司 Targeted treatment of cancers with dysregulated fibroblast growth factor receptor signaling
JP2023533903A (en) * 2020-05-15 2023-08-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 Method for treating cancer with oral formulation of FGFR4 inhibitor

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399633B1 (en) 1999-02-01 2002-06-04 Aventis Pharmaceuticals Inc. Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
DE19959546A1 (en) 1999-12-09 2001-06-21 Rhone Poulenc Rorer Gmbh Pharmaceutical preparation for the treatment of tumor diseases
MXPA02007005A (en) 2000-01-18 2004-09-06 Aventis Pharma Inc PSEUDOPOLYMORPH OF ()CIS2(2CHLOROPHENYL)5, 7DIHYDROXY8[4R(3SHYDROXY1METHYL)PIPERIDINYL]4Hminu s;1BENZOPYRAN4ONE.
JP2003520798A (en) 2000-01-18 2003-07-08 アベンテイス・フアーマシユーチカルズ・インコーポレーテツド Ethanol solvent compound of (-)-cis-2- (2-chlorophenyl) -5,7-dihydroxy-8 [4R- (3S-hydroxy-1-methyl) piperidinyl] -4H-1-benzopyran-4-one
US20050004007A1 (en) 2000-09-12 2005-01-06 Steven Grant Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitiors and cellular differentiation agents
BRPI0307057B8 (en) 2002-01-22 2021-05-25 Warner Lambert Co compounds 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
PL2256106T3 (en) 2003-07-22 2015-08-31 Astex Therapeutics Ltd 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
AU2006207322A1 (en) 2005-01-21 2006-07-27 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors and further antitumor agents
ES2552338T3 (en) 2005-01-21 2015-11-27 Astex Therapeutics Limited Pharmaceutical compounds
AU2006207321B2 (en) 2005-01-21 2012-09-06 Astex Therapeutics Limited Pharmaceutical compounds
WO2008007113A2 (en) 2006-07-14 2008-01-17 Astex Therapeutics Limited Pharmaceutical combinations
AR054425A1 (en) 2005-01-21 2007-06-27 Astex Therapeutics Ltd PIPERIDIN ADDITION SALTS 4-IL-ACID AMID 4- (2,6-DICLORO-BENZOILAMINO) 1H-PIRAZOL-3-CARBOXILICO.
JP2008255008A (en) 2005-07-19 2008-10-23 Tokyo Medical & Dental Univ Synoviocyte proliferation inhibitor
JO3235B1 (en) 2006-05-26 2018-03-08 Astex Therapeutics Ltd Pyrrolopyrimidine compounds and their uses
EP2043635A2 (en) 2006-06-29 2009-04-08 Astex Therapeutics Limited Pharmaceutical combinations
JP2009543770A (en) 2006-07-14 2009-12-10 アステックス・セラピューティクス・リミテッド Combinations of pyrazole derivatives for the inhibition of CDK and GSK
JP2009544602A (en) 2006-07-21 2009-12-17 アステックス・セラピューティクス・リミテッド Medical use of cyclin-dependent kinase inhibitors
EP1918376A1 (en) * 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
US7902147B2 (en) 2007-11-05 2011-03-08 Duke University Chronic lymphocytic leukemia prognosis and treatment
GEP20125502B (en) * 2008-05-23 2012-04-25 Novartis Ag Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
ES2522346T3 (en) 2008-08-22 2014-11-14 Novartis Ag Pyrrolopyrimidine compounds as CDK inhibitors
PA8852901A1 (en) 2008-12-22 2010-07-27 Lilly Co Eli PROTEIN CINASE INHIBITORS
AR079257A1 (en) * 2009-12-07 2012-01-04 Novartis Ag CRYSTAL FORMS OF 3- (2,6-DICLORO-3-5-DIMETOXI-PHENYL) -1- {6- [4- (4-ETIL-PIPERAZIN-1-IL) -PENYL-AMINO] -PIRIMIDIN-4- IL} -1-METHYL-UREA AND SALTS OF THE SAME
UY33226A (en) 2010-02-19 2011-09-30 Novartis Ag PIRROLOPIRIMIDINE COMPUTERS DEUTERATED AS INHIBITORS OF THE CDK4 / 6
RU2589696C2 (en) * 2010-04-13 2016-07-10 Новартис Аг COMBINATION INCLUDING CYCLIN-DEPENDENT KINASE 4 INHIBITOR OR CYCLIN-DEPENDENT KINASE 6 INHIBITOR (CDK4/6) AND mTOR INHIBITOR FOR TREATING CANCER
EP3381920B1 (en) 2010-10-25 2019-03-27 G1 Therapeutics, Inc. Cdk inhibitors
AR083797A1 (en) 2010-11-10 2013-03-20 Novartis Ag DIMETHYL ACID SUCCINATE 7-CYCLOPENTIL-2- (5-PIPERAZIN-1-IL-PIRIDIN-2-IL-AMINO) -7H-PIRROLO- [2,3-D] PIRIMIDIN-6-CARBOXILICO, PROCESS FOR PREPARE IT, INTERMEDIARIES OF SUCH SYNTHESIS AND PREPARATION PROCESS OF THE SAME
PT2688887E (en) 2011-03-23 2015-07-06 Amgen Inc Fused tricyclic dual inhibitors of cdk 4/6 and flt3
WO2013006368A1 (en) * 2011-07-01 2013-01-10 Novartis Ag Combination therapy
AR091876A1 (en) * 2012-07-26 2015-03-04 Novartis Ag PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
WO2014097125A1 (en) 2012-12-20 2014-06-26 Novartis Ag Pharmaceutical combination comprising binimetinib
JOP20200097A1 (en) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc Androgen receptor modulator and uses thereof
SI2968290T1 (en) 2013-03-15 2020-02-28 G1 Therapeutics, Inc., Transient protection of normal cells during chemotherapy
EP4005573A1 (en) * 2013-08-14 2022-06-01 Novartis AG Combination therapy for the treatment of cancer
BR112016008110B1 (en) 2013-10-18 2019-07-02 Eisai R&D Management Co., Ltd. FGFR4 PYRIMIDINE INHIBITOR COMPOSITION, PHARMACEUTICAL COMPOSITION UNDERSTANDING COMPOUND AND THERAPEUTIC USES OF THESE
WO2016025650A1 (en) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
CN104529904B (en) 2015-01-09 2016-08-31 苏州明锐医药科技有限公司 The preparation method of Bo Maxini
WO2016126889A1 (en) 2015-02-03 2016-08-11 G1 Therapeutics, Inc. Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy
ES2864712T3 (en) * 2015-04-14 2021-10-14 Eisai R&D Man Co Ltd Crystalline FGFR4 Inhibitor Compound and Uses Thereof

Also Published As

Publication number Publication date
JP7190425B2 (en) 2022-12-15
CA3034875A1 (en) 2018-03-01
RU2769251C2 (en) 2022-03-29
KR102466192B1 (en) 2022-11-14
ES2966469T3 (en) 2024-04-22
CN109803684B (en) 2022-08-23
KR20190040996A (en) 2019-04-19
AU2017315357B2 (en) 2022-12-01
IL264950B1 (en) 2023-09-01
JP2019528302A (en) 2019-10-10
RU2019108259A3 (en) 2020-11-24
WO2018039324A1 (en) 2018-03-01
AU2017315357A1 (en) 2019-02-28
EP3503923B1 (en) 2023-10-04
IL264950A (en) 2019-05-30
CN109803684A (en) 2019-05-24
BR112019003722A2 (en) 2019-05-28
RU2019108259A (en) 2020-09-25
MX2019002115A (en) 2019-07-08
EP3503923A1 (en) 2019-07-03
CA3034875C (en) 2024-05-28
US20190175598A1 (en) 2019-06-13
IL264950B2 (en) 2024-01-01

Similar Documents

Publication Publication Date Title
SG11201806404SA (en) Systems and methods for storing and sharing transactional data using distributed computer systems
SG11201809669RA (en) Use of glutamate modulating agents with immunotherapies to treat cancer
SG11201808990QA (en) Compositions for topical application of compounds
SG11201901577SA (en) Method and system for fast tracking navigation of blockchains via data manipulation
SG11201901472TA (en) Combination therapies for the treatment of hepatocellular carcinoma
SG11201804814YA (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201803905RA (en) A hair styling appliance
SG11201907496RA (en) Cyclic di-nucleotides compounds for the treatment of cancer
SG11201810465RA (en) Compositions and methods related to engineered fc constructs
SG11201810600WA (en) Fxr (nr1h4) modulating compounds
SG11201804901WA (en) Compounds for the treatment of cancer and inflammatory disease
SG11201910198UA (en) Multibiotic agents and methods of using the same
SG11201805888SA (en) Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
SG11201803906PA (en) Control of cellular redox levels
SG11201807088SA (en) Method and device for handling allocation request
SG11201811237WA (en) Combination therapies
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201806133UA (en) Intermediates in the synthesis of eribulin and related methods of synthesis
SG11201903885RA (en) Secure key management
SG11201806825RA (en) A data source system agnostic fact category partitioned information repository and methods for the insertion and retrieval of data using the information repository
SG11201805874VA (en) Method and apparatus for adding notification objects
SG11201908531WA (en) Combination therapies for the treatment of breast cancer
SG11201809527UA (en) Methods of treating circadian rhythm sleep disorders